Sahsen Ventures

Sahsen Ventures is a Seattle-based venture capital firm founded in 2016 by Bryan White and Christine White, former leaders at Quellos and BlackRock Alternative Advisors. Named after the hummingbird revered by Pacific Northwest native peoples, the firm invests across both for-profit and nonprofit sectors. Beyond capital, Sahsen takes a dual philanthropic-and-equity approach: funding basic research through grants while backing for-profit companies to scale practical, translational innovations. Its team brings deep institutional investing experience from managing billions in alternative assets. Sahsen focuses on life sciences, environmental sustainability, and social justice, including health, safety, and education. Notable investments include Parse Biosciences (acquired by Qiagen), Recursion Pharmaceuticals, Sana Biotechnology, Lyell Immunopharma, Archon Bio, and Terray Therapeutics. The firm primarily invests at Seed and Series A stages across life sciences, high-tech, and sustainability-tech sectors. Investment criteria emphasize mission alignment with supporting "Earthbound life" alongside attractive risk-adjusted returns; specific check sizes aren't publicly disclosed. Send over the next link whenever you're ready.